In vitro behaviour of osteoblasts cultured on orthopaedic biomaterials with different surface roughness, uncoated and fluorohydroxyapatite-coated, relative to the in vivo osteointegration rate.
The effects of two surfaces with different roughness (Low Roughness, LR: Ra: 5.6-5.9 microm; High Roughness, HR: Ra: 21.5-22.5 microm), uncoated and fluorohydroxyapatite(FHA)-coated, were investigated in MG-63 osteoblasts. At 72 hours, cells proliferated on biomaterials more slowly than in the control group (p < 0.0001), the proliferation rate was higher on FHA-coated LR than uncoated HR (p = 0.037). Collagen-I production was positively affected by the LR surface (p = 0.001) as compared to controls, while it was significantly lower (p = 0.0001) in the HR surfaces. Compared to controls, LR and HR surfaces led to enhanced production of TGF-beta1, further improved by FHA (FHA-coated LR: p = 0.007; FHA-coated HR p < 0.0001 respectively). ALP, OC, IL-6 and TNF-alpha levels were not significantly different from the controls. Results suggest that collagen-I production could be useful in predicting the in vivo osteointegration rate of biocompatible biomaterials observed in previous studies.
Fini
M
M
Experimental Surgery, Department-Research Institute Codivilla-Putti, Rizzoli Orthopaedic Institute, Bologna, Italy.
Giardino
R
R
Borsari
V
V
Torricelli
P
P
Rimondini
L
L
Giavaresi
G
G
Nicoli Aldini
N
N
D000469:Alkaline Phosphatase / Q000032:analysis; D001672:Biocompatible Materials / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D024042:Collagen Type I / Q000032:analysis; D006801:Humans; D006882:Hydroxyapatites / Q000494:pharmacology*; D015850:Interleukin-6 / Q000032:analysis; D008855:Microscopy, Electron, Scanning; D016348:Osseointegration / Q000187:drug effects* / Q000502:physiology; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D015675:Osteocalcin / Q000032:analysis; D016212:Transforming Growth Factor beta / Q000032:analysis; D053773:Transforming Growth Factor beta1; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D001672:Biocompatible Materials; D024042:Collagen Type I; D006882:Hydroxyapatites; D015850:Interleukin-6; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D014409:Tumor Necrosis Factor-alpha; C116586:fluorohydroxyapatite; D015675:Osteocalcin; D000469:Alkaline Phosphatase